More results on: 
Download PDF files on: 
Download Word files on: 
Images on: 
Video/Audio on: 
Download PowerPoint on: 
More results from.edu web: 
Best Viewed With GFS!
Help
Add this page to your book
Show book (0 pages)
Suggest pagesTesaglitazar
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (2S)-2-Ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 251565-85-2  |
| ATC code | None |
| PubChem | CID 208901 |
| UNII | 6734037O3L  |
| KEGG | D01274 |
| ChEMBL | CHEMBL521632 |
| Chemical data | |
| Formula | C20H24O7S |
| Mol. mass | 408.46 |
|
|
 (what is this?) (verify) |
|
Tesaglitazar (AZ 242) is a peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for type 2 diabetes.1
The drug had completed several phase III clinical trials,2 however in May, 2006 AstraZeneca announced that it had discontinued further development.3
References
- ^ Wilding JP, Gause-Nilsson I, Persson A (2007). "Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes". Diab Vasc Dis Res 4 (3): 194–203. doi:10.3132/dvdr.2007.040. PMID 17907109.
- ^ "GALIDA (tesaglitazar) Clinical Trial Report Summaries". AstraZeneca. Retrieved 2008-03-17.dead link
- ^ "AstraZeneca Discontinues Development of GALIDA (tesaglitazar)". AstraZeneca. 2006-05-04. Retrieved 2012-07-23.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
 |  | |
